

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of) **Mail Stop PCT**
Paul Taylor Martin)
Application No.: 10/551,619) Group Art Unit: To Be Assigned
Filed: September 30, 2005) Examiner: To Be Assigned
For: AMYLOID-SPECIFIC PEPTIDES AND) Confirmation No.:
USES THEREOF) Certificate of Mailing
I hereby certify that this correspondence is being
deposited with the United States Postal Service via
Express Mail Post Office to Addressee service under 37
C.F.R. §1.10 on May 9, 2006 and is addressed to:
Mail Stop PCT, Commissioner for Patents, P.O. Box
1450, Alexandria, VA 22313-1450.
By: 
Kim A. Cabello

FIRST INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure as set forth in 37 C.F.R. § 1.56, the accompanying information is being submitted in accordance with 37 C.F.R. §§ 1.97 and 1.98.

Pursuant to 37 C.F.R. § 1.98, a copy of each of the documents cited is enclosed. However, a copy of the listed U.S. patent application publication is not enclosed since it is no longer required according to the July 11, 2003 waiver of the requirement for copies of cited U.S. patents and U.S. patent application publications in national patent applications filed after June 30, 2003 and international applications entering the national stage under 35 U.S.C. § 371 after June 30, 2003.

The documents are being submitted within three (3) months of the filing or entry of the national stage of this application or before the first Office Action on the merits, whichever is later. Since these documents are being filed within the time period set forth in 37 C.F.R. § 1.97(b), no fee or statement is required.

To assist the Examiner, the documents are listed on the attached form PTO-1449. It is respectfully requested that an Examiner initialed copy of this form be returned to the undersigned.

Respectfully submitted,

BUCHANAN INGERSOLL PC

Date May 9, 2006

By: Susan B. Fuller
Susan B. Fuller
Registration No. 51,979

P.O. Box 1404
Alexandria, Virginia 22313-1404
(858) 509-7300

Substitute for form 1449A/PTO & 1449B/PTO				<i>Complete if Known</i>		
FIRST INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Application Number	10/551,619	
Sheet	1	of	1	Filing Date	September 30, 2005	
				First Named Inventor	Paul Taylor Martin	
				Examiner Name		
				Attorney Docket Number	1034123-000167	

U.S. PATENT DOCUMENTS						
Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document			Issue/Publication Date (MM-DD-YYYY)
	US2002/018674					

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS		Cited in Spec
					Translation	Partial Translation	

NON-PATENT LITERATURE DOCUMENTS									
Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.								
	Bajaj et al. "Ultra-Rare-Event Detection Performance of a Custom Scanning Cytometer on a Model Preparation of Fetal nBRCs" <i>Cytometry</i> , (2000). 39:285-294.								
	Cherny et al."Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice". <i>Neuron</i> , (2001) 30:665-676.								
	Kang et al. "The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor" <i>Nature</i> , (1987). 325:733-736.								
	Kang et al. "Identification of peptides that specifically bind Aβ ₁₋₄₀ amyloid in vitro and amyloid plaques in Alzheimer's disease brain using phage display" <i>Neurobiology of Disease</i> , (2003). 14:146-156.								
	Mazzuchelli et al. "Cell-Specific Peptide Binding by Human Neutrophils" <i>Blood</i> , (1999). 93:1738.								
	Morris and Price "Pathologic Correlates to Nondemented Aging, Mild Cognitive Impairment, and Early-Stage Alzheimer's Disease" <i>J. Mol. Neurosci.</i> , (2001). 17:101-118.								
	Parks et al."Neurotoxic Aβ peptides increase oxidative stress <i>in vivo</i> through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition <i>in vitro</i> " <i>J. Neurochem.</i> , (2001). 76:1050-1060.								
	Roher et al. "Purification, ultrastructure, and chemical analysis of Alzheimer disease amyloid plaque core protein" <i>Proc. Natl. Acad. Sci. USA</i> , (1986). 83:2662-2666.								
	Selkoe "Alzheimer's Disease: Genes, Proteins, and Therapy" <i>Physiol Rev</i> , (2001). 81:741-766.								
	Smith and Scott "Libraries of Peptides and Proteins Displayed on Filamentous Phage" <i>Methods. Enzymol.</i> , (1993). 217:228-257.								
	Stine et al."The Nanometer-Scale Structure of Amyloid-β Visualized by Atomic Force Microscopy" <i>J. Prot. Chem.</i> , (1996). 15:193-203.								
	Tucker et al. "The Plasmid System Is Induced by and Degrades Amyloid-β Aggregates" <i>J. Neurosci.</i> , (2000). 20:3937-3946.								
	Watson et al. (1987). In <i>Molecular Biology of the Gene</i> , 4 th ed., The Benjamin/Cummings Publ. Co., p.224.								

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.
CA 103447.1